Market Insights

The FDA's accelerated approval for gene therapies: A Q&A with Josh McGee

Once the pandemic subsided, there was a spike in gene therapy approvals, with four therapies released in 2022, which sent a clear message that the Food and Drug Administration is reshifting its focus to progressive therapies, such as a new therapeutic treatment of glaucoma.